The retina is a thin, light-sensitive layer located at the back of the eye. It contains two main types of photoreceptors: rods, which are responsible for vision in low-light conditions, and cones, which enable color and daylight vision. In dogs affected by PRA5, a mutation disrupts the normal function and survival of these photoreceptor cells. Over time, the cells begin to deteriorate and die, leading to a gradual loss of visual capability.
Clinical signs of PRA5 typically develop later in life, although the exact age of onset may vary depending on breed and genetic background. The earliest symptom is usually night blindness, where dogs have difficulty seeing in dim light or darkness. Owners may notice that affected dogs hesitate in poorly lit areas, become reluctant to go outside at night, or bump into objects in low-light environments. As the disease progresses, daytime vision also becomes impaired, leading to difficulty navigating familiar spaces, reduced spatial awareness, and trouble recognizing obstacles.
Eventually, PRA5 leads to complete blindness. Despite this, the condition is not painful, and most dogs adapt well to vision loss by relying on their other senses, including smell and hearing. With proper care and environmental consistency, affected dogs can continue to live comfortable and fulfilling lives even after vision loss.
The PRA5 DNA Health Test is designed to detect the specific genetic mutation associated with this form of Progressive Retinal Atrophy. The test is simple, safe, and non-invasive, typically performed using a cheek swab or blood sample. The collected DNA is analyzed in a specialized laboratory to determine whether the dog carries zero, one, or two copies of the mutation. Because DNA remains stable throughout life, testing can be performed at any age, including before clinical symptoms appear.
Results are generally reported in three categories:
- Clear (Normal): The dog does not carry the PRA5 mutation and cannot pass it to offspring.
- Carrier: The dog carries one copy of the mutation but is usually unaffected during its lifetime. However, it can pass the mutation to future generations.
- Affected/At Risk: The dog carries two copies of the mutation and has a high likelihood of developing Progressive Retinal Atrophy (PRA5) with progressive vision loss.
Genetic testing for PRA5 is highly valuable for breeders, veterinarians, and dog owners. Breeders can use results to make informed mating decisions that help reduce or eliminate the mutation from breeding populations while maintaining healthy genetic diversity. Avoiding carrier-to-carrier breeding significantly reduces the risk of producing affected puppies.
For dog owners, understanding a dog’s genetic status allows for early preparation and supportive care. Dogs identified as at risk can benefit from environmental adjustments such as maintaining consistent home layouts, using scent and sound cues, and ensuring safe navigation spaces. Routine ophthalmic examinations can also help track disease progression. While there is currently no cure for PRA5, supportive management can significantly improve quality of life.
The Progressive Retinal Atrophy (PRA5) Health Test is a reliable genetic screening tool that supports responsible breeding practices, promotes canine eye health, and helps reduce the impact of this inherited retinal degeneration in future generations.
